Atocha Romero Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

12/2023	Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations-a retrospective cohort study.
10/2023	Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer. Reply.
8/2023	Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
1/2023	Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques.
1/2023	Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.
12/2022	Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study.
9/2022	Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer.
4/2022	Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy.
2/2022	Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.
1/2022	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Atocha Romero Research Topics

Disease

29	Neoplasms (Cancer) 01/2023 - 12/2015
26	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2023 - 10/2016
20	Breast Neoplasms (Breast Cancer) 02/2023 - 04/2011
7	Disease Progression 09/2022 - 09/2017
6	Lung Neoplasms (Lung Cancer) 01/2023 - 08/2017
3	Adenocarcinoma of Lung 12/2023 - 01/2019
3	Circulating Neoplastic Cells 03/2020 - 10/2016
2	Neoplasm Metastasis (Metastasis) 12/2023 - 12/2015
1	Brain Neoplasms (Brain Tumor) 12/2023
1	Polyps 12/2023
1	Adenocarcinoma 12/2023
1	Pruritus (Itching) 01/2023
1	Proteinuria 01/2023
1	Fatigue 01/2023
1	Hypertension (High Blood Pressure) 01/2023
1	Residual Neoplasm 02/2022
1	Pericardial Effusion 01/2021
1	Pleural Effusion (Pleural Effusions) 01/2021
1	Ascites 01/2021
1	Teratocarcinoma 01/2021
1	Febrile Neutropenia 11/2020
1	Genetic Risk Score 01/2020
1	Fibrosis (Cirrhosis) 01/2019
1	Triple Negative Breast Neoplasms 01/2019
1	Chromosome Fragility 01/2019
1	Ovarian Neoplasms (Ovarian Cancer) 04/2015

Drug/Important Bio-Agent (IBA)

12	Biomarkers (Surrogate Marker)IBA 04/2022 - 12/2015
9	Circulating Tumor DNAIBA 10/2022 - 01/2017
9	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 04/2011
6	Estrogen ReceptorsIBA 01/2022 - 12/2017
5	Anaplastic Lymphoma KinaseIBA 12/2023 - 08/2017
5	NivolumabIBA 10/2023 - 11/2020
5	Tyrosine Kinase InhibitorsIBA 12/2022 - 04/2020
4	Cell-Free Nucleic AcidsIBA 09/2022 - 10/2016
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 09/2022 - 01/2021
3	B7-H1 AntigenIBA 01/2023 - 01/2021
3	RNA (Ribonucleic Acid)IBA 01/2023 - 03/2020
2	alectinibIBA 12/2023 - 12/2022
2	Proteins (Proteins, Gene)FDA Link 09/2022 - 01/2019
2	Tumor Biomarkers (Tumor Markers)IBA 01/2022 - 01/2017
2	Nucleic AcidsIBA 01/2022 - 12/2016
2	human ERBB2 proteinIBA 01/2022 - 01/2020
2	Progesterone Receptors (Progesterone Receptor)IBA 01/2022 - 01/2020
2	osimertinibIBA 01/2021 - 06/2020
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 01/2019
2	Hormones (Hormone)IBA 01/2021 - 01/2019
2	Transcription Factors (Transcription Factor)IBA 01/2020 - 11/2017
2	Formaldehyde (Formol)FDA Link 02/2019 - 12/2015
2	ParaffinIBA 02/2019 - 12/2015
2	AnthracyclinesIBA 03/2012 - 04/2011
1	atezolizumabIBA 01/2023
1	Drug CombinationsIBA 01/2023
1	Bevacizumab (Avastin)FDA Link 01/2023
1	Programmed Cell Death 1 ReceptorIBA 01/2023
1	Complementarity Determining Regions (Complementarity Determining Region)IBA 09/2022
1	Epithelial Cell Adhesion MoleculeIBA 02/2022
1	N-acetyltalosaminuronic acid (NAT)IBA 02/2022
1	Interferon Type IIBA 01/2022
1	ElementsIBA 01/2021
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021
1	Cadherins (E-Cadherin)IBA 01/2021
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021
1	ErbB Receptors (EGF Receptor)IBA 01/2021
1	Lipase (Acid Lipase)FDA Link 11/2020
1	Carboplatin (JM8)FDA LinkGeneric 11/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 11/2020
1	ceritinibIBA 04/2020
1	CrizotinibIBA 04/2020
1	Phenobarbital (Luminal)FDA Link 01/2020
1	Tamoxifen FDA LinkGeneric 01/2020
1	rho GTP-Binding Proteins (rho GTP-Binding Protein)IBA 01/2020
1	Homeodomain Proteins (Proteins, Homeobox)IBA 01/2020
1	olaparibIBA 01/2019
1	Messenger RNA (mRNA)IBA 01/2019
1	diepoxybutaneIBA 01/2019
1	PlatinumIBA 01/2019
1	A-Form DNA (A-DNA)IBA 01/2019
1	AcidsIBA 12/2016
1	tetraethylpyrazine (TEP)IBA 10/2016
1	MicroRNAs (MicroRNA)IBA 01/2016
1	3' Untranslated Regions (3' UTR)IBA 01/2016
1	NucleotidesIBA 04/2015
1	EnzymesIBA 03/2012
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 04/2011

Therapy/Procedure

10	Therapeutics 01/2023 - 10/2016
7	Drug Therapy (Chemotherapy) 10/2023 - 03/2012
5	Neoadjuvant Therapy 04/2022 - 11/2020
4	Immunotherapy 04/2022 - 01/2021
3	Radiotherapy 02/2023 - 01/2021
3	Cardiopulmonary Resuscitation (CPR) 01/2022 - 01/2021
1	Gastrectomy 12/2023
1	Aftercare (After-Treatment) 01/2022
1	Drug Tapering 09/2017